EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023)

Fernando Rivera, Federico Longo, Marta Martín Richard, Paula Richart, Maria Alsina, Alberto Carmona, Ana Belén Custodio, Ana Fernández Montes, Javier Gallego, Tania Fleitas Kanonnikoff

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03600-7 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Fernando Rivera und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain. fernando.rivera@scsalud.es. Hauptthemen laut MEDLINE: Stomach Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, the incidence is lower and GC represents the tenth most frequent tumor and the seventh cause of cancer mortality. Molecular biology knowledge allowed to better profile patients for a personalized therapeutic approach. In the localized setting, the multidisciplinary team discussion is fundamental for planning the therapeutic approach. Endoscopic resection in very early stage, perioperative chemotherapy in locally advanced tumors, and chemoradiation + surgery + adjuvant immunotherapy for the GEJ are current standards. For the metastatic setting, biomarker profiling including Her2, PD-L1, MSS status is needed. Chemotherapy in combination with checkpoint inhibitors had improved the outcomes for patients with PD-L1 expression. Her2 positive patients should receive antiHer2 therapy added to chemotherapy. We describe the different evidences and recommendations based on the literature.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsHumansSpainBiomarkers, TumorMedical OncologyImmunotherapyErb-b2 Receptor Tyrosine KinasesImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Gastric cancerImmunotherapyPrecision medicineSupportive careTumor biology

Substanzen

Biomarkers, TumorErb-b2 Receptor Tyrosine KinasesImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain. fernando.rivera@scsalud.es.
  • Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Medical Oncology Department, ICO Duran i Reynals, Barcelona, Spain.
  • Medical Oncology Department, Hospital La Fe, Valencia, Spain.
  • Medical Oncology Department, Hospital Universitario de Navarra (HUN), Pamplona, Spain.
  • Medical Oncology Department, Hospital Morales Meseguer, Murcia, Spain.

Zitieren

APA

Rivera, F., Longo, F., Martín Richard, M., Richart, P., Alsina, M., Carmona, A., Custodio, A. B., Fernández Montes, A., Gallego, J., & Fleitas Kanonnikoff, T. (2024). SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023). Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03600-7

Vancouver

Rivera F, Longo F, Martín Richard M, Richart P, Alsina M, Carmona A, et al. SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023). Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03600-7

BibTeX
@article{Rivera2024,
  author = {Rivera, Fernando and Longo, Federico and Martín Richard, Marta and Richart, Paula and Alsina, Maria and Carmona, Alberto and Custodio, Ana Belén and Fernández Montes, Ana and Gallego, Javier and Fleitas Kanonnikoff, Tania},
  title = {SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023)},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03600-7}
}
Kostenlos starten →